Gene promoter methylation is associated with increased mortality among women with breast cancer by Xu, Xinran et al.
Gene Promoter Methylation is Associated with Increased Mortality
among Women with Breast Cancer
Xinran Xu1, Marilie D. Gammon6, Yujing Zhang7, Yoon Hee Cho7, James G. Wetmur2,3,
Patrick T. Bradshaw6, Gail Garbowski7, Hanina Hibshoosh8, Susan L. Teitelbaum1, Alfred I.
Neugut9,10, Regina M. Santella7, and Jia Chen1,4,5
1Department of Community and Preventive Medicine, Mount Sinai School of Medicine
2Department of Microbiology, Mount Sinai School of Medicine
3Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine
4Department of Pediatrics, Mount Sinai School of Medicine
5Department of Oncological Science, Mount Sinai School of Medicine
6Department of Epidemiology, University of North Carolina at Chapel Hill
7Department of Environmental Health Sciences, Columbia University
8Department of Pathology, Columbia University
9Department of Epidemiology, Columbia University
10Department of Medicine, Columbia University
Abstract
To better understand breast cancer etiology and progression, we explored the association between
promoter methylation status of three breast cancer related genes (BRCA1, APC and p16) and survival
in a large cohort of women with breast cancer. About 800 archived tumor tissues were collected from
women diagnosed with a first primary invasive or in situ breast cancer in 1996–1997. The vital status
of the participants was followed through the end of year 2005 with a mean follow up time of 8.0
years. Promoter methylation was assessed by methylation-specific PCR (for BRCA1) and
MethyLight (for APC and p16). The association of promoter methylation and breast cancer mortality
was evaluated by Cox-proportional hazards models. Methylated promoters were found in 59.0%,
48.4% and 3.6% of the tumor samples for BRCA1, APC and p16, respectively. Breast cancer-specific
mortality was strongly associated with promoter methylation of p16 [HR and 95% CI: 3.53(1.83–
6.78)], whereas the associations with of BRCA1 and APC were less pronounced [HR and 95% CI:
1.81(1.18–2.78) and 1.46(0.98–2.17), respectively]. Similar associations were observed with all-
cause mortality. As the number of methylated genes increased, the risk of breast cancer-specific
mortality also increased in a dose-dependent manner (p, trend=0.01). Importantly, even with our
results stratified by hormone receptor status, promoter methylation of the three genes remained
predictive of mortality. Our results suggest that promoter methylation could be promising epigenetic
markers to be considered for breast cancer survival.
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INTRODUCTION
During the past several years, early detection and novel treatments have improved survival
rates in breast cancer [1]. However, there is still an urgent need for biomarkers that can reliably
be used to predict clinical outcome of breast cancer patients [2]. Recently, evidences emerge
as gene promoter methylation status could predict cancer survival. A study reported that
methylation in APC was associated with an increased risk of prostate cancer–specific mortality
in two cohort of patients [3].
Although the causal relationship is still being debated, evidence has shown that promoter
hypermethylation is associated with silencing of many crucial genes in the neoplastic process
[4]. This phenomenon has also been reported in a large panel of genes in breast cancer [5].
Breast cancer gene 1(BRCA1) encodes a multifunctional protein involved in DNA repair,
control of cell-cycle checkpoints, protein ubiquitinylation and chromatin remodeling [6].
About 5–50% of familial breast cancers could be explained by inherited mutations of
BRCA1 in different populations [7]. BRCA1 status may potentially be used as a prognostic
marker as studies have shown that BRCA1 mutated breast cancer is associated with poor
survival [8]. BRCA1 promoter methylation was found be to positively associated with breast
cancer 5-year mortality [9]. The adenomatous polyposis coli (APC) gene is a tumor suppressor
gene associated with both familial and sporadic cancer [10]. Its best understood function is
destabilization of β̣-catenin and aberrant nuclear and cytoplasmic localization of β-catenin in
human breast cancer [11]. Promoter methylation in APC was observed in breast cancer [12]
and was associated with poor prognosis [13]. p16INK4A is a predominant tumor suppressor gene
in a wide variety of human cancers and p16 promoter methylation has been identified as a
major mechanism for p16 inactivation in a number of primary cancers [14]. Methylation of the
5’ promoter has been observed in both human breast cancer cell lines and 20–30% of breast
cancers [15]. However, its role in breast cancer progression is less known. Despite a high rate
of loss of heterozygosity at these three loci in breast cancer, somatic mutations of the remaining
allele are rare in sporadic cancer [5]. Therefore, other mechanisms for loss of function must
exist. DNA methylation has been proposed as an alternative mechanism to inactivate these
genes [16].
We previously reported that intakes of B vitamins as well as common polymorphisms in one-
carbon metabolizing genes were associated with breast cancer survival in the population-based
Long Island Breast Cancer Study Project [17]. Herein, we investigated promoter methylation
status of a panel of breast cancer genes in relation to clinical/pathological factors and survival
in the context of breast cancer.
MATERIALS AND METHODS
Study population
We utilized the resources of the parent case-control as well as the follow-up study of the Long
Island Breast Cancer Study Project, a population-based study. Briefly, eligible cases were
women residing in Nassau or Suffolk counties, who spoke English, were 20 years of age or
older, and were newly diagnosed with in situ or invasive breast cancer between August 1, 1996,
and July 31, 1997. A total of 1,508 women with breast cancer participated in the baseline, case-
control study interview. As previously reported [18], at the time of the first primary breast
cancer diagnosis, the mean age was 58.8 years (range: 25.1–98.1); 94% were white, 4% were
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African American, and 2% were other; 235 (15.6%) had carcinoma in situ and 1273 (84.4%)
had invasive tumors. Case women, or their next of kin, were interviewed again approximately
five years after diagnosis. Medical records were abstracted during the case-control study and
again as part of the follow-up study. Details of the study design have been described previously
[18–20]. The study protocol was approved by the Institutional Review Boards of the
collaborating institutions. REMARK criteria were used through this report [21].
Exposure Assessment
Participants information used in this study were obtained as part of the 1) case-control
(baseline) in-home interview; 2) follow-up telephone interview; and 3) medical record
abstraction. The questionnaires were administrated to assess the demographic characteristics,
breast cancer-related factors, and treatment information. Treatment information provided by
the subject at the time of the follow-up interview was found to be in excellent agreement with
the data abstracted from the medical record [radiation therapy (Kappa = 0.97), chemotherapy
(Kappa = 0.96), and hormone therapy (Kappa = 0.92)], thus we used the self-reported data.
Characteristics of the tumor, including estrogen and progesterone receptor (ER/PR) status,
were extracted from medical records. Among cases with this information available, 583
(58.9%) were ER+/PR+; 143 (14.4%) were ER+/PR−; 52 (5.3%) were ER−/PR+; and 212
(21.4%) were ER−/PR−. For a smaller subset of women, we were able to obtain medical record
information on tumor size (n=321) and node involvement (n=327).
Tumor block retrieval and DNA extraction
Archived pathology blocks were requested from the 33 hospitals in the Long Island study area
and successfully retrieved for 962 (66.2%) women. After the review by trained pathologists,
the tumor tissues from 859 subjects (89.3%) were available for laboratory analyses. We
compared the demographic and clinico/pathological features between cases with or without
tumor block available for methylation analysis in our study. Although most characteristics are
similar between these two groups, some factors were different. Case women who had tumor
samples available for methylation analysis tended to be older (mean age 59.6 vs. 57.9 years;
p=0.005); to have an invasive tumor (87.8% vs. 80.1%; p<0.001); and to be post-menopausal
(70.7% vs. 64.6%; p=0.01).
The paraffin blocks from each case participant were used to generate 2x 10 micron thick slides.
Tumor tissues were isolated from paraffin sections by microdissection. Tumor DNA was
isolated by adding 30 µl of proteinase K-digestion buffer (50mM Tris, pH 8.1, 1 mM EDTA,
0.5% Tween 20, 10 µg/ml proteinase K) to the tube and by incubating overnight at 37°C.
Proteinase K was inactivated incubating the samples at 95°C for 10 min and centrifugation.
Analysis of gene promoter methylation
Tumor DNA first underwent bisulfite modification to convert unmethylated cytosine residues
to uracil using the CpGnome DNA Modification Kit (Chemicon International, Purchase, NY)
following the protocol from the manufacturer. BRCA1 promoter methylation was determined
by methylation-specific PCR (MSP) as described previously [9]. The MethyLight assay was
used for determining the methylation status of APC and p16 as described previously [22,23].
The percentage of methylation was calculated by the 2−ΔΔCT method, where ΔΔCT =
(CT,Target-CT,Actin)sample - (CT,Target-CT,Actin) fully methylated DNA[24] and multiplying by 100.
Samples containing ≥ 4% fully methylated molecules were designated as methylated, whereas
samples containing ≤ 4% were designated as unmethylated. We obtained methylation data on
851 tumor tissues for BRCA1 and on 800 for APC or p16, respectively. The main reason for
missing methylation data was insufficient DNA that was obtained from the tumor blocks.
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The National Death Index was used to ascertain all-cause and breast cancer-specific mortality.
Information on vital status of our study subjects was requested from the National Death Index
(NDI), using social security numbers, birth date and other information provided to us by the
study subject at the time of the baseline interview. The NDI provided us with potential death
matches, including date and cause of death. These data were manually inspected by our research
study staff to determine whether the information provided was a likely match to individual
subjects within our study cohort. Among the entire cohort of 1508 women diagnosed with
breast cancer in 1996–1997, 308 (20.2%) deaths occurred by December 31, 2005, of which
164 (53.2%) were due to breast cancer. Among the subset of women with methylation data
available (n = up to 851), a total of 122 (14.3%) deaths (all-cause mortality) were observed,
of which 79 (64.8%) were due to breast cancer. The mean follow up time was 8.0 years (range:
0.3–9.4).
Statistical Analysis
The association between gene promoter methylation status of the tumor tissue and the clinical/
pathological factors was examined using the chi-square statistic or fisher exact test for
categorical variables and by the two-sample t-test for continuous variables [25]. Percentage
methylation for APC and p16 was dichotomized to methylated or unmethylated using a cut-
off of 4%. The Cox proportional hazard regression [26] was used to estimate the hazard ratio
(HR) and 95% confidence interval (CI) for the association between gene promoter methylation
status and breast cancer-specific as well as all-cause mortality. Potential confounding by other
factors might influence survival among breast cancer patients was evaluated by adjustment in
the Cox model. These factors include age at diagnosis, ER/PR status [positive group = ER and
PR both positive (ER+/PR+) vs. negative group = any negative receptor (ER+/PR−, ER−/PR
+, ER−/PR−)], cancer stage (in situ vs. invasive), menopausal status (pre- vs. post-), race (white
vs. other), family history of breast cancer (a mother, sister or daughter) and history of benign
breast disease diagnosed by biopsy. If eliminating a covariate from the full Cox regression
model changed the effect estimate by 10% or more, the covariate was considered a confounder
and kept in the model [27]. Otherwise that covariate was dropped from the multivariate model.
None of the covariates tested met this criterion, and thus, only results from the crude model
are presented. The HRs and 95% CIs for the association between promoter methylation and
mortality stratified by ER/PR status of the case were also estimated by Cox model. All statistical
analyses were performed using SAS statistical software version 9.1(SAS Institute, Cary, NC).
RESULTS
The prevalence of the promoter methylation status of BRCA1, APC and p16, as assessed in the
archived breast tumor samples of this population-based cohort of up to 851 women (including
104 in situ and 747 invasive cases), was 59.0%, 48.4% and 3.6% for BRCA1, APC and p16,
respectively.
Table 1 summarizes the relationship between gene promoter methylation and clinical/
pathological factors. BRCA1 promoter methylation was more frequent in cancers that were
classified as invasive (p=0.02) and among premenopausal women (p=0.05). BRCA1 promoter
methylation was more frequent in cancers with at least one node involved (p=0.003) and with
tumor size greater than 2 cm (p=0.001). Promoter methylation status of APC and p16 were not
associated with factors examined in Table 1.
As shown in Table 2, promoter methylation status of three genes, BRCA1, APC and p16, was
associated with breast cancer-specific mortality in this study population. Compared to cases
with an unmethylated promoter, those who had a methylated promoter had an 81% increased
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risk of dying from breast cancer at the end of follow up for BRCA1 (HR: 1.81; 95% CI: 1.18–
2.78) and a 46% increased risk for APC (HR: 1.46; 95% CI: 0.98–2.17). The strongest effect
was observed for p16, with a more than 3-fold increase of risk of dying from breast cancer at
the end of follow up (HR: 3.53; 95% CI: 1.83–6.78). Similar associations were observed for
all-cause mortality (Table 2). These associations were not attenuated after adjusting for other
well-established prognostic factors such as age at diagnosis and ER/PR status (data not shown).
We also explored whether there was heterogeneity by cancer type (in situ vs. invasive), but
results did not vary substantially (data not shown).
When considering promoter methylation status of the three genes simultaneously, a dose-
response association emerged; as the number of methylated genes increased, the magnitude of
the association with breast cancer-specific mortality also increased (p, trend=0.011) (Table 3).
Cases with all three genes methylated had the highest risk of dying from breast cancer at the
end of follow up (HR: 3.58; 95% CI: 1.52–8.42). Similar but weaker associations were
observed for all-cause mortality (p, trend=0.056).
When we stratified our analysis by ER/PR status (both receptors positive vs. any negative
receptor) (Figure 1), breast cancer-specific mortality was higher among women with
methylated gene promoter regardless of the hormone receptor status of the tumor. In general,
it appeared that women with the worse prognosis were those with ER/PR negative breast tumor
with methylated gene promoter; for example, among the ER/PR negative subgroup those who
also had a methylated BRCA1 promoter, the hazards ratio was more than doubled (HR and
95% CI: 2.58;1.18–5.62) compared to those with unmethylated BRCA1 promoter. An exception
to this general pattern were women with ER/PR positive tumors who also had methylated
p16 promoter; their risk of dying from breast cancer was more than 5-fold (HR and 95% CI:
5.19; 1.84–14.66) compared to those with unmethylated p16 promoter.
When survival analysis was performed according to treatment groups, the relationship between
gene promoter methylation status and survival did not differ between those who received the
treatments (radiation, chemotherapy, and/or hormonal therapy) and those who did not (data
not shown).
DISCUSSION
Only part of the variation in the risk of mortality among women with breast cancer can be
explained by known pathologic and clinical parameters [28]. Thus, to effectively reduce the
disease burden of breast cancer, identification of genetic, environmental and behavioral factors
that influence survival among breast cancer survivors is needed. We chose to examine promoter
methylation status of three genes that were selected based on their biologic importance in breast
carcinogenesis [29]. Our study is based on data drawn from a large population-based sample,
and is the first to report on the prognostic value of gene promoter methylation status in breast
cancer in an epidemiologic study. Although our analysis of methylation-survival association
was based on a sub-sample of a population-based parent study, we can quantify any potential
biases due to tumor tissue being unavailable for analyses, which is different from the clinic
based studies that are unable to quantify to which segment of the population that is
generalizable. The population-based study design, in which cases encompassed a broad range
of ages and were drawn from a defined geographic area, yields results that are more
generalizable than a series of cases from a narrow age range or from a single institution. In
addition, the relatively large sample size allows multiple factors to be taken into consideration
in studying associations, with the ability to conduct stratified analyses and adjustment in
multivariate models.
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We found promoter methylation status of three tumor suppressor genes, BRCA1, APC and
p16, was associated with breast cancer-specific mortality in our study. The potential prognostic
value of mutation in these genes has been explored. A recent review [30] summarized
differences in survival outcome in relation to BRCA1 germline mutations. Carriers of a gene
mutation had functionally defective proteins, usually resulting in some loss of function.
Promoter methylation represented an alternative mechanism for loss of function of these tumor-
suppressors. The observed decreased survival associated with methylated gene promoters
corroborates the previous findings on mutations. More interestingly, when the number of
dysregulated genes (presumably by aberrant promoter methylation) increased, the survival
outcome deteriorated, as illustrated by the dose-dependent relationship between the number of
methylated genes and mortality (Table 3). These findings lend support to the notion that
promoter methylation could silence expression of these of tumor-suppressor genes, affecting
disease progression.
We found that the gene promoter methylation status of BRCA1, APC and p16 could further
identify cases with statistically significantly different survival profiles among patients with the
same ER/PR status (Figure 1). The estrogen receptor (ER) and progesterone receptor (PR) play
an important role in regulating growth and differentiation of normal breast epithelium and are
well established prognostic factors of breast cancer [31]. Positive receptor status correlates
with favorable prognostic features including a lower rate of cell proliferation and histologic
evidence of tumor differentiation [32]. Our findings that promoter methylation of BRCA1,
APC and p16 can further categorize cases with the same ER/PR status with respect to survival
profile may have clinical significance; such information may potentially aid in tailoring
treatment strategies based on these epigenetic markers. However, some subgroup analyses are
based on small numbers of women (i.e. low frequency of p16 hypermethylation), as reflected
in the wide confidence intervals; these results should be interpreted with caution.
The relationship between clinical/pathological factors and gene promoter methylation status
has not been well-examined. One study found a higher frequency of APC methylation in
inflammatory breast cancer [33] while another reported that APC methylation was less frequent
in ER-negative and HER2/neu-negative breast cancers [34]. One report showed that p16
hypermethylation was more frequent among ER-negative cases than ER-positive cases [35].
In our analysis, only BRCA1 methylation status showed some correlations with clinical/
pathological factors of breast cancer. BRCA1 promoter methylation was more frequent in
invasive than in in situ carcinomas. Different methylation profiles observed in subtypes of
breast cancer tissues may imply different etiologic roles of methylation in these disease
phenotypes.
Limitations in our study include the following concerns. First, some known, validated,
independent breast cancer prognostic factors were not completed on the medical records for
all cases. We adjusted for tumor size and node involvement (individually and jointly) on the
subset of the population with available information and found the associations were not
attenuated. Second, gene expression was not measured in the tumor tissues, thus we could not
explore the functional consequence of DNA methylation. Studying gene expression in archived
samples (i.e. formaldehyde fixed paraffin-embedded tissues) has been problematic [36] and
conflicting results are found in the literature [37]. Nevertheless, the fact that our results
corroborate those from gene mutation studies suggests that promoter methylation indeed results
in gene silencing or loss of gene function. Third, Long Island Breast Cancer Study Project was
conducted in multiple hospitals, so the treatment information was not as detailed as data from
a single institutional study. This limited our ability to conduct a more detailed investigation on
the predictive effect of gene methylation status. For those cases who had treatment information
available, we performed separate analyses according to treatment groups within that subset of
population; no substantial differences were observed. Lastly, one potential limitation is that
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we can not rule out the possibility that for some subjects, cause of death may have been
misclassified. The accuracy of cause of death on death certificates has been questioned [38],
and is an ongoing issue in most cohort studies of cause-specific mortality. However, the
National Death Index completeness has been found to be reasonably validated [39], and thus
it remains a standard source of mortality data for epidemiologic research.
In summary, we examined promoter methylation status of three breast cancer genes and
explored their relationship with clinical/pathological factors as well as breast cancer survival.
Our results indicate that promoter methylation of BRCA1, APC and p16 could offer additional
value in breast cancer prognosis beyond established prognostic factors such as ER/PR status.
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Kaplan–Meier curve for breast cancer-specific survival of gene promoter methylation by ER/
PR status among a population-based cohort of women diagnosed with a first primary breast
cancer in 1996–1997 on Long Island, NY and followed for vital status through the end of 2005.
Numbers showed before the hazards ratio (HR) are numbers of case / death. (U: unmethylated;
M, methylated)
Xu et al. Page 12




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Xu et al. Page 16
Table 3
Number of methylated genes in relation to breast cancer-specific and all-cause mortality among a population-
based cohort of women diagnosed with a first primary breast cancer in 1996–1997 on Long Island, NY and
followed for vital status through the end of 2005.
No. of genes
methylated








  0 137 11 1.00(ref.)
  1 356 43 1.52(0.78–2.94)
  2 268 35 1.70(0.86–3.35)




  0 137 25 1.00(ref.)
  1 356 77 1.20(0.77–1.89)
  2 268 66 1.42(0.90–2.25)
  3 38 11 1.76(0.87–3.58)
Breast Cancer Res Treat. Author manuscript; available in PMC 2010 June 1.
